Physician profile
Christopher Green
NPI 1902284342
$11,850.29
in general payments reported to CMS, 2019-2025
68 companies · $2,492 in 2025
The $2,492 reported for 2025 was more than what 97% of General Practice providers received nationally (typical 2025 total: $105).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $354 · 2020: $947 · 2021: $1,871 · 2022: $1,398 · 2023: $2,252 · 2024: $2,536 · 2025: $2,492.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,280.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,279.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,217.87 | 2021-2025 | |
| Lilly USA, LLC | $1,152.98 | 2019-2025 | Mounjaro, Zepbound, Emgality |
| Amgen INC. | $978.80 | 2019-2025 | Evenity, Prolia, Repatha |
| Astrazeneca Pharmaceuticals LP | $840.93 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Novo Nordisk INC | $746.15 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $589.85 | 2020-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Janssen Pharmaceuticals, INC | $467.78 | 2020-2024 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $289.19 | 2019-2024 | Jardiance, Spiriva Respimat, Stiolto Respimat |
| Takeda Pharmaceuticals U.S.A., INC. | $285.44 | 2019-2024 | Eohilia, Trintellix |
| Sanofi-Aventis U.S. LLC | $270.93 | 2019-2025 | |
| Dexcom, INC. | $241.38 | 2022-2025 | Dexcom G6 Transmitter |
| Exact Sciences Corporation | $232.95 | 2023-2025 | Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $230.18 | 2021-2025 | |
| Pfizer INC. | $229.74 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $194.30 | 2019-2025 | Gardasil 9, Belsomra, Capvaxive |
Show all 68 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Green listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.